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Introduction
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase member of the insulin receptor superfamily. Although ALK is expressed at high levels prenatally, its expression is dramatically decreased in healthy adult tissues. Aberrant expression of full-length ALK occurs in neuroblastoma (George et al., 2008) . In addition, novel fusion-ALK proteins that possess constitutive kinase activity, and contribute to oncogenic processes are generated by chromosomal translocation or inversion of the ALK gene. Two of these fusion ALK proteins nucleophosmin (NPM-ALK) and echinoderm microtubule-associated protein-like 4 (EML4-ALK) have been validated as driving oncogenes in a subset of anaplastic large cell lymphomas and non-small cell lung carcinomas, respectively (Morris et al., 1994; Soda et al., 2007) . The clinical validation of EML4-ALK as a therapeutic target by crizotinib has provided compelling evidence for the importance of ALK in oncology (Shaw et al., 2011) .
Compound 1 ((E)-4-fluoro-N-(6-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-1-((1s,4s)-4-(isopropylcarbamoyl)cyclohexyl)-1H-benzo[d]imidazol-2(3H)-ylidene)benzamide)
, is a member of a new class of potent and selective anaplastic lymphoma kinase inhibitor with potential application in the treatment of cancer (Lewis et al., 2012) . In vitro screening of compound 1 resulted in excellent inhibitory activity against the ALK enzyme (IC50 = 1 nM) and ALK expressing Karpas-299 cells (4 nM) (Lewis et al., 2012) . Rat in vivo studies showed acceptable PK with a CL of 0.8 L/hr/kg, a t1/2 of 5.6 hr, and MRT of 8 hrs (Lewis et al., 2012) .
Based on potency and preliminary rodent pharmacokinetics, compound 1 was selected as a candidate to advance into efficacy studies in mice. However, during bioanalysis it was found that the compound was subject to extensive hydrolysis to a resultant primary amine product (M1). Enzyme mediated hydrolytic metabolism of compound 1 was examined to determine whether or not it would be a liability in the further development of this molecule for potential use in humans.
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Although not as common as cytochrome P450 mediated oxidations, hydrolysis reactions play an important role in the metabolism of xenobiotics (Testa and Mayer, 2003) . A variety of hydrolytic enzymes have been implicated in the hydrolysis of esters, thioesters, amides, and epoxides. These hydrolytic enzymes include carboxylesterases, cholinesterases, organophosphatases, and amidases/peptidases. Cholinesterases and aminopeptidases are the most commonly associated with the hydrolysis of amide bonds (Uetrecht and Trager, 2007) .
Species difference in amide hydrolysis is well precedented. For example, considerable species differences in extent of hydrolysis was observed for lidocaine forty years ago (Keengham and Boyes, 1972) . With regards to compounds containing biaryl amide links, species differences in extent of hydrolysis have been reported for ameltolide (Potts et al., 1989) , the anticonvulsant agent D2624 (Martin et al., 1997) , pranulkast, (Luan et al., 1997) , piroxicam (Hobbs and Twomey, 1981) , and more recently a bile acid Takeda G-protein coupled receptor 5 (TGR5) agonist (Eng et al., 2010) and the Bruton's Tyrosine Kinase Inhibitor GDC-0834 (Liu et al., 2011) .
Species specific enzyme mediated amide hydrolysis reactions in drug discovery often present multiple problems, including high CL in PK, instability in in vitro assays that may contain the hydrolytic enzymes, and instability in bioanalytical matrices such as blood or plasma.
Instability in in vitro and ex vivo assays may lead to erroneous results and potentially causes the subsequent termination of a promising candidate. Therefore, early identification and examination of the hydrolytic process(es) can be used to design experiments that deliver more accurate results, provide rationale for the progression (or early termination) of a lead molecule, or support the design of hydrolytically stable analogs that might offer better success in development.
In early development, knowledge of the hydrolysis mediated metabolism of a lead molecule may influence the approach taken to predict human pharmacokinetics prior to advancement of the compound to the clinic. For example, although they performed kinetic In a discovery setting, extrahepatic metabolism such as hydrolysis in plasma, is occasionally proposed as a possible explanation for poor predictivity of in vitro-in vivo extrapolation (IVIVE) based upon data obtained from liver microsomes or hepatocytes. To our knowledge, there are no reports in the literature that deal with an IVIVE method for hydrolysis which takes into account plasma hydrolysis, saturation kinetics, and contribution of NADPH dependent metabolism. In this paper, we report our experiences with compound 1, a novel potent ALK inhibitor that is rapidly enzymatically hydrolyzed in mouse plasma and liver microsomes. We report our rationale for the successful guidance of compound progression and the use of IVIVE of the hydrolysis reaction to drive an informed decision. In addition, the contributions of hydrolysis in plasma and liver versus NADPH-dependent metabolism in vitro are considered in this context. was determined in triplicate by equilibrium dialysis, using the Rapid Equilibrium Dialysis device (Thermo Scientific, Rockford, IL). Three hundred microliter aliquots of plasma containing 0.1 µM, 0.5 µM or 2 µM test compound were dialyzed against 500 µL of phosphate buffered saline for 7 h at 37 °C in an incubator maintained at 5% CO 2 . Preliminary experiments with selected compounds indicated that a 7 h incubation time was sufficient to achieve equilibrium. Since some test compounds were rapidly hydrolyzed in plasma, plasma was pre-incubated for 20 min in the presence of 100 µM diisopropyl flourophosphate (DFP) to inactivate hydrolytic enzymes.
Recovery of test compounds in the presence of DFP was >80%, indicating DFP did an adequate job of preventing hydrolysis. Aliquots of the post-dialysis buffer were transferred into an equal volume of blank plasma. Samples of the dialyzed plasma were transferred to an equal volume of buffer. Samples were extracted with acetonitrile containing internal standard (tolbutamide), then centrifuged at 3500 g for 15 min and analyzed by LC-MS/MS as described below. The fraction unbound in plasma was calculated by dividing the amount of drug found in the post dialysis buffer by the amount found in the dialyzed plasma.
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Blood to plasma ratio (BP)
. BP was determined in vitro after incubation of compound with and without DFP in fresh whole blood. Blood was warmed to 37°C and compound was spiked to a concentration of 1 µM. After incubation for 1 h the blood samples were processed for plasma.
Reference plasma was also spiked with compound to a concentration of 1 µM. The same incubations were performed after pre-incubation for 20 min with 100 µM of DFP to inhibit amide hydrolysis. Recovery of test compounds in the presence of DFP was >80%. Samples were extracted with 6 volumes of acetonitrile containing internal standard, centrifuged, and analyzed on the LC-MS/MS system described below. BP was calculated by dividing the peak area observed in the reference plasma (representing nominal blood concentration) by the peak area observed in the treated plasma (representing plasma concentration).
Pharmacokinetic studies in mice. All animal procedures were conducted under protocols approved by the Amgen (Cambridge, MA) Institutional Animal Care and Use Committee. Male CD-1 mice were purchased from Taconic (Germantown, NY). Mice (60) were housed in a humidity-and temperature-controlled environment subject to a 12 h:12 h light:dark cycle and had access to water and a standard laboratory diet ad libitum. The animals designated for oral administration were fasted overnight prior to dosing and food was returned 2 h post-dose. plasma was flash frozen on dry ice and stored at -80 °C until required for follow-up analysis.
Plasma samples were analyzed using the LC-MS/MS method described below.
Analysis of pharmacokinetic samples. The LC-MS/MS system consisted of a Waters
Acquity UPLC system (Waters) and an API4000 mass spectrometer ( Calibration curve standards and QC samples were prepared in mouse plasma at concentrations ranging from 0.3 to 10000 ng/mL for each compound. Fifty microliters of each plasma sample, calibration standard, and QC sample were extracted by adding 6 volumes of a mixture containing 0.1% formic acid in water and an internal standard. The samples were mixed by vortexing and centrifuged. The resulting supernatants were diluted with an equal volume of water.
Samples were injected onto an Acquity UPLC Phenyl 1.7µm BEH column (2.1X50 mm Waters) with a 0.5 µm PEEK guard filter. Analytes were separated using a gradient solvent system consisting of two components: solvent A (water containing 0.1% formic acid) and solvent B (acetonitrile containing 0.1% formic acid). The percentage of solvent B was increased in a linear fashion from 10% to 95% over 2 min, then maintained at 95% for an additional 0.5 min; flow rate was 0.6 mL/min.
Raw data was collected using Sciex Analyst 1.5.1 (Applied Biosystems, Foster City, CA)
residing on a computer running a Windows XP operating system. Following peak area integration, the data was exported to the Small Molecules Discovery Assay ( Calculation of kinetic constants. Kinetic constants apparent V max and K m were determined for compound 1, compound 2, compound 3, and compound 4 from depletion experiments with mouse plasma and liver microsomes by assuming that Michaelis-Menten kinetics were sufficient to describe the metabolic processes. Kinetic constants for the hydrolysis pathways in plasma or liver microsomes in the absence of NADPH were determined using the relationship:
where CL int , hydrolysis is the observed CL int due to hydrolysis in plasma or in liver microsomes in the absence of NADPH, and C is the concentration of test compound in the incubation.
CL int observed in incubations with mouse liver microsomes in the presence of NADPH (CL int , NADPH ) reflects the contribution of hydrolysis together with NADPH-dependent processes.
Therefore, the apparent kinetic constants for NADPH-dependent metabolism were estimated while considering the contribution of the kinetics of the hydrolysis pathway, as measured in incubations with mouse liver microsomes in the absence of NADPH. In other words, the Metabolite formation velocity (v) was also simulated using the estimated apparent V max and K m values for hydrolysis or NADPH-dependent metabolism in plasma and liver microsomes using the relationship:
Prediction of CL from in vitro data. CL caused by metabolism in the plasma and liver were predicted separately using the corresponding apparent kinetic constants. Maximum CL int (CL int,max ) for hydrolysis in plasma, hydrolysis in liver or NADPH-dependent metabolism in liver was calculated by:
CL caused by hydrolysis in plasma (CL ,plasma ) was considered independent of blood-flow and was predicted by the relationship .5 g liver per kg body weight in mice, respectively; f u,mic is the fraction unbound in microsomes; f ub is the fraction unbound in blood, equal to the fraction unbound in plasma (f up ) divided by the blood-to-plasma concentration ratio (Rb); and Qh is the hepatic blood flow, or 5.4 L/(h*kg) in mice. Since a value for SF1 is not available for mouse liver, the value for SF1 used was that determined for rat liver (Houston and Galetin, 2008) , and was assumed to reasonably represent mouse liver.
Results
Compound 1 Studies. As a prelude to conducting murine efficacy studies, we investigated the PK disposition of compound 1 in mice. During analysis, it was discovered that compound 1 rapidly degraded in plasma. Figure 1 and the authentic standard were identical.
Since the hydrolytic reaction was facilitated by increased temperature (data not shown), a method was developed that minimized the time from sample collection to extraction and the exposure of the matrix to temperatures greater than 4 0 C during storage and processing.
Quality control samples processed under similar conditions (see experimental) were within 20 % of nominal concentrations across the standard curve (relative standard deviations 5%-20%). In addition, no hydrolysis products were detected in the processed QC samples or standards.
This method was used for analysis of compound 1 in mouse plasma and a mouse IV PK study with compound 1 was conducted successfully. As shown in Table 1 , compound 1 was rapidly cleared from plasma with a half life of 1 hr and CL of 5.5 L/hr/kg. Compound 1 was stable to incubation with rat, dog, and human plasma and liver microsomes, indicating that the observed hydrolysis phenomenon was mouse specific. proceeded to dose mice orally at 20, 50, and 100 mpk. Figure 3 shows the plasma levels of compound 1 and its hydrolysis product after PO dosing with 20, 50, 100 mpk. At a dose of 100 mpk, significant target coverage appeared to be achievable. It can be observed that the exposures were not dose proportional, with a decrease in CL/F increasing with dose (Table 3 ).
In addition, the proportion of the exposure of hydrolysis product to compound 1 was significantly higher at the lower doses. The data suggested saturation kinetics, and additional results and discussion are given below. In response to the results above, the medicinal chemistry efforts continued toward the design of compounds with attenuated hydrolysis in mouse plasma.
Minimizing Hydrolysis. Discovery efforts focused on minimizing hydrolysis in mouse plasma
showed that the biggest impact on mouse plasma stability was achieved by altering the nature of the substitutuents on the benzamide ring ( Figure 4 ). Bulky electron withdrawing groups appear to decrease the rate while no substitution or substitution with electron donating groups appears to increase the rate. Figure 5 shows the PK profiles of three selected compounds (compounds 2, 3, and 4) with half-lives of 4 to 8 hrs. Compound 1 was included for comparison. Table 1 shows the non-compartmental PK parameters of the 4 compounds. A decrease in CL associated with increased plasma stability was observed. Figure 6 shows the kinetics of metabolism of selected ALK inhibitors versus concentration in mouse plasma. The V max and K m values for the hydrolysis of these compounds in mouse plasma are shown in Table 4 . The V max for compound 1 hydrolysis in plasma was significantly higher than the other compounds while the K m s for all were comparable and lower than 1 µM.
Kinetics of hydrolysis in mouse plasma.
Kinetics of metabolism in mouse liver microsomes. Considering that both hydrolysis and
NADPH-dependent metabolic pathways could contribute to the elimination of these compounds, the concentration-dependent metabolism kinetics were also determined in liver microsomes in the absence (hydrolysis only) and presence (hydrolysis + NADPH-dependent metabolism) of (Table 4) , Therefore, the primary effect of chemical modification was to reduce extent of hydrolysis among these ALK inhibitor analogs.
IVIVE. Plasma protein binding, microsomal binding, and blood to plasma ratio were measured after inactivation of the hydrolytic enzymes with diisopropylfluorophosphate.
Recovery of drug in the presence of DFP was >80%, indicating inhibition of hydrolytic activity.
Blood to plasma concentration ratio for each compound was determined to be close to 1 (0.90-1.02 with SD 0.02-0.19), therefore f ub was taken to be equivalent to f up . Table 5 shows the 
Discussions
Compound 1 Hydrolysis. The observation of a susceptibility to plasma hydrolysis of compound 1 early in the drug discovery phase could have presented significant obstacles in the progression of this class of ALK inhibitors. However, the sequence of experiments described here quickly quantified the obstacles and allowed a rational decision regarding the progression of compounds to the efficacy testing phase. The first problem was the stability of the compound in plasma. This led to inability to accurately quantify the plasma levels. Modification of the bioanalytical method to prevent hydrolysis post sample-collection enabled us to measure the plasma levels and obtain PK parameters that correctly reflected the properties of the compound in-vivo. The second obstacle to the progression was the possible presence or absence of the hydrolytic cleavage pathway in other species. Experiments to address the species selectivity showed that the enzymatic hydrolytic pathway was highly specific to mouse with no hydrolysis observed in vitro (liver microsomes and plasma) in rat, dog, and human. Furthermore, in vivo, the hydrolysis pathway was not detectable in the plasma of PK samples from rats and dogs.
Species specificity with regard to enzyme mediated hydrolytic cleavage is not uncommon and has been observed for related amides (Eng et al., 2010; Hobbs and Twomey, 1981; Luan et al., 1997; Liu et al., 2011; Martin et al. 1997; Potts et al., 1989) . High CL due to hydrolysis in mouse was problematic because of the desire to use readily available immune-compromised animals for the evaluation of in vivo efficacy in xenograft models of disease. Examining the PO PK closely showed a saturation of elimination as exemplified by the disproportional increase in exposure and the increase in bioavailability between the two lowest dose groups. Furthermore, the ratio of M1 exposure relative to compound 1 decreased with increased dose suggesting that the hydrolytic pathway was saturation limited. Metabolite M1 was also tested for activity in our ALK inhibition assays and showed no potency. Exposures levels achieved in the mice used in disease efficacy models were similar to those observed in the PK studies and full data will be Minimizing Hydrolysis. The medicinal chemistry efforts attempted to design potent analogs with reduced hydrolytic potential. Minimizing enzyme mediated hydrolytic cleavage via changes to the substitution patterns of a benzamide moiety has been described by Douch and Gahagan in the metabolism of niclosamine (Douch and Gahagan, 1977) . Their work showed that substituents ortho to the benzamide bond substantially decreased hydrolytic potential.
Although this decrease in hydrolysis was attributed to steric hindrance, electronic effects may also be implicated since substantial decrease in hydrolysis may also be achieved by para substitution (Testa and Mayer, 2003) . In the case of the ALK inhibitors described here, ortho substitution was not tolerated, most probably due to the distortion of the co-planar conformation which was required for an optimum interaction with the ALK protein (Lewis et al., 2012) . Studies of meta or para substitution on the benzamide moiety demonstrated clear SAR. Di-substitutions and bulkier electronegative groups decreased the rate of hydrolysis. Unfortunately, the ALK-cell potencies of the most hydrolytically stable compounds decreased significantly relative to the less stable analogs. For example, the cell potencies of the compounds 1, 2, 3 and 4 were 4 nM, 6 nM, 333 nM, and 90 nM, respectively. The in vitro plasma t 1/2 for these same compounds (from Fig 3) , compound 1, 2, 3, and 4 were 0.2 hr, 2.9 hr, 8.2 hr, and 8.5 hr respectively. The IV PK of the compounds with minimized hydrolysis showed decreased CL and better exposures.
The decrease in systemic CL exhibited by hydrolytically stable compounds suggested that the in vitro stability in plasma qualitatively related to the in vivo exposure. This led us to investigate the IVIVE relationship to learn if in vitro experimental results could quantitatively predict CL when hydrolysis contributes to elimination.
IVIVE. In our IVIVE experiments several features were notable. First, in initial experiments, it was found that the mouse microsomal CL int of compound 1 at 0.01 µM was significantly higher than that at 1 µM; 898 µL/(min*mg) versus 110 µL/(min*mg). This suggested Secondly, since these ALK inhibitors were also hydrolyzed in mouse plasma, in vitro plasma CL int values were also experimentally obtained. The CL int values in plasma were calculated using a similar approach to the microsomal work.
The results show that the contribution of plasma hydrolysis to the overall CL is likely minor even for the compounds with the shortest plasma half-lives. This illustrates the potential pitfalls of following only rates of plasma hydrolysis to screen compounds for stability. Rowland and Riegleman (Rowland and Riegleman,1968) have also elegantly demonstrated the relatively minor contribution of hydrolysis in blood to the total CL of acetylsalicylic acid via hydrolysis to salicylic acid. It seems that half-life determinations in plasma (or blood) can potentially be used help detect the presence of a hydrolysis mechanism but it should not be automatically inferred that plasma (or blood) is the main tissue responsible for elimination, even for compounds with short half-lives in plasma (or blood) in vitro. Subsequent scaling exercises, however, using in vitro half-life data and appropriate scaling factors can help estimate the contribution of hydrolysis in plasma to CL relative to the contribution of elimination or metabolism by other organs.
Thirdly, for microsomal CL int experiments in mouse, both hydrolysis and NADPHdependent metabolic pathways were considered. Metabolite identification clearly showed that the only metabolite formed in microsomes in the absence of NADPH was the hydrolysis product.
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Explanations for the phenomenon have been proposed, including reduced (or a lack of) enzyme activity in various in vitro preparations compared to in vivo, study designs that do not consider saturation kinetics, metabolism by organs other than the liver, passive renal or hepatic elimination, impact of hepatic uptake transporters, and elimination by active transport.
Conclusive explanations for lack of predictive IVIVE are rarely provided. For compounds that are hydrolyzed by esterases, metabolism in extrahepatic tissues could likely be a major reason for under prediction, since hydrolytic enzymes are present throughout the body. In the present example, contrary to expectations, hydrolysis in plasma appeared to contribute little to systemic CL, and consideration of hepatic metabolism alone was sufficient to achieve a reasonable prediction of CL. However, the possibility of some relatively minor contribution to CL by other tissues cannot be ruled out.
In summary, in vitro kinetic and in vivo PK studies indicated that the primary CL pathway of compound 1 in mouse, amide hydrolysis, was saturation limited, and that plasma levels of free drug exceeding in-vitro IC50 were achievable at higher doses. Reducing the extent of hydrolysis was possible through chemical modification of the compound 1 structure leading to compound 2 with better exposure at lower doses. Compound 2 has substantial efficacy in a murine xenograft model of ALK driven cancer (Lewis et al, 2012) . Rendering this chemotype more stable to hydrolysis was associated with significant loss in potency against ALK in vitro.
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